ストックスクリーナーアプリを入手
41.15
6.17%
2.39
アフターアワーズ：
40.87
-0.28
-0.68%
前日終値:
$38.76
開ける：
$39.08
24時間の取引高:
2.09M
Relative Volume:
1.63
時価総額：
$3.91B
収益：
$47.30M
当期純損益:
$-225.97M
株価収益率:
-17.51
EPS:
-2.35
ネットキャッシュフロー:
$-188.86M
1週間 パフォーマンス:
+11.25%
1か月 パフォーマンス:
+28.07%
6か月 パフォーマンス:
-6.26%
1年 パフォーマンス:
+342.00%
1日の値動き範囲:
$39.02
$41.17
1週間の範囲:
$36.05
$41.17
52週間の値動き範囲:
$6.76
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
名前
Scholar Rock Holding Corp
セクター
電話
857-259-3860
住所
301 BINNEY STREET, CAMBRIDGE, MA
SRRK を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
41.15 | 3.51B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.55 | 123.00B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
547.93 | 59.66B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.81 | 41.84B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
577.92 | 33.98B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
279.16 | 27.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-11-26 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-10-07 | 繰り返されました | H.C. Wainwright | Buy |
| 2024-03-28 | 開始されました | Raymond James | Strong Buy |
| 2023-10-25 | アップグレード | Jefferies | Hold → Buy |
| 2023-04-03 | 再開されました | Piper Sandler | Overweight |
| 2022-09-19 | 再開されました | H.C. Wainwright | Buy |
| 2022-07-12 | 開始されました | Truist | Buy |
| 2022-03-23 | 開始されました | H.C. Wainwright | Buy |
| 2021-12-22 | ダウングレード | Jefferies | Buy → Hold |
| 2021-11-19 | 開始されました | Piper Sandler | Overweight |
| 2021-04-26 | 再開されました | Credit Suisse | Outperform |
| 2021-01-11 | 開始されました | Credit Suisse | Outperform |
| 2021-01-06 | 開始されました | JP Morgan | Overweight |
| 2020-03-12 | 開始されました | Robert W. Baird | Outperform |
すべてを表示
Scholar Rock Holding Corp (SRRK) 最新ニュース
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives $42.67 Average PT from Brokerages - MarketBeat
What makes Scholar Rock Holding Corporation stock price move sharplyFree AI-Powered Stock Predictions - Newser
How Scholar Rock Holding Corporation stock performs during market volatilityCapital Preservation Investment Ideas - Newser
Why Scholar Rock Holding Corporation stock attracts strong analyst attentionFree Stock Selection with 300% Return - Newser
Scholar Rock (NASDAQ:SRRK) Trading Up 6.5%What's Next? - MarketBeat
Scholar Rock CSO Mo Qatanani sells $828,898 in shares By Investing.com - Investing.com Nigeria
Scholar Rock CSO Mo Qatanani sells $828,898 in shares - Investing.com Australia
Scholar Rock Q1 2025 slides: apitegromab advances toward FDA approval with priority review - Investing.com Nigeria
Scholar Rock Holding Corporation(NasdaqGS:SRRK) dropped from Russell 3000E Value Index - MarketScreener
Scholar Rock Holding Corporation (NASDAQ:SRRK) Director Jeffrey S. Flier Sells 20,316 Shares - MarketBeat
Truist reiterates buy rating on Scholar Rock stock amid SMA therapy potential - Investing.com Nigeria
Is Scholar Rock Holding Corp. overvalued or undervalued? - MarketsMojo
Analysts Offer Insights on Healthcare Companies: Eli Lilly & Co (LLY), Exelixis (EXEL) and Abbott Laboratories (ABT) - The Globe and Mail
Scholar Rock's Breakthrough SMA Drug Shows Positive Phase 3 Results, FDA Fast-Tracks Review - Stock Titan
Scholar Rock (NASDAQ:SRRK) Trading Down 5.7% – Time to Sell? - Defense World
Scholar Rock Holding Corporation (NASDAQ:SRRK) Receives Consensus Recommendation of “Buy” from Analysts - Defense World
Muscle-preserving drugs could generate over $30 billion in sales by 2035, TD Cowen says - MarketScreener
Scholar Rock (SRRK) Jumps 16.6% After Successful Weight Loss Drug Trial - Insider Monkey
Scholar Rock (NASDAQ:SRRK) Receives Outperform Rating from Wedbush - MarketBeat
Why Scholar Rock Shares Are Soaring Today - The Globe and Mail
Scholar Rock (NASDAQ:SRRK) Shares Gap UpWhat's Next? - MarketBeat
Transcript : Scholar Rock Holding CorporationSpecial Call - MarketScreener
Scholar Rock Stock Soars on Biopharma Firm's Weight-Loss Drug Trial Results - Yahoo Finance
Scholar Rock's Atrophy Drug When Combined With Eli Lilly's Zepbound Shows Around 55% Better Muscle Preservation In Weight Loss Study - Benzinga
Scholar Rock stock soars after drug shows promise in preserving lean mass during weight loss - Investing.com Australia
Trading Day Triumph: Scholar Rock Holding Corp (SRRK) Ends at 31.15, a -3.05 Surge/Plunge - DWinneX
Scholar Rock's drug helps Zepbound patients retain more muscle in trial - marketscreener.com
Scholar Rock (SRRK) Surges 14% Following EMBRAZE Trial Results | SRRK Stock News - GuruFocus
Scholar Rock (SRRK) Surges After Promising Weight Loss Trial - GuruFocus
Scholar Rock Reports Positive Results From Phase 2 EMBRAZE Study - Nasdaq
Scholar Rock stock gains on weight loss data (SRRK:NASDAQ) - Seeking Alpha
Scholar Rock (SRRK) Reveals Phase 2 Trial Success of Apitegromab with Tirzepatide | SRRK Stock News - GuruFocus
Scholar Rock's drug helps patients on Zepbound preserve muscle in trial - MarketScreener
Scholar Rock’s apitegromab preserves lean mass during weight loss - Investing.com
Scholar Rock's drug helps preserve lean mass in mid-stage trial - marketscreener.com
Scholar Rock's Breakthrough Drug Shows 55% Better Muscle Preservation in Weight Loss Study - Stock Titan
Scholar Rock’s apitegromab preserves lean mass during weight loss By Investing.com - Investing.com Nigeria
Notable Two Hundred Day Moving Average CrossSRRK - Nasdaq
Scholar Rock Holding Corp Executives Sell Shares to Cover Tax Obligations - TradingView
GAMMA Investing LLC Buys 30,140 Shares of Scholar Rock Holding Corporation (NASDAQ:SRRK) - MarketBeat
GAMMA Investing LLC Has $962,000 Stock Holdings in Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Rhumbline Advisers Purchases 7,491 Shares of Scholar Rock Holding Co. (NASDAQ:SRRK) - Defense World
Jefferies Names Akero Therapeutics, Scholar Rock As Biotech Companies With Takeover Potential, But Retail Isn’t Pleased By Stocktwits - Investing.com India
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule - marketscreener.com
Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Yahoo Finance
Scholar Rock at Goldman Sachs Conference: Strategic Focus on SMA By Investing.com - Investing.com Nigeria
Transcript : Scholar Rock Holding Corporation Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-11-2025 09 - MarketScreener
Truist Financial Sticks to Its Buy Rating for Nurix Therapeutics (NRIX) - The Globe and Mail
Scholar Rock Holding Co. (NASDAQ:SRRK) Stake Increased by California State Teachers Retirement System - MarketBeat
Scholar Rock (NASDAQ:SRRK) Trading Up 5.9%Here's What Happened - MarketBeat
Scholar Rock Holding Corp (SRRK) 財務データ
収益
当期純利益
現金流量
EPS
3.40%
2.49%
大文字化:
|
ボリューム (24 時間):